Supreme Court refuses to hear Saffran v Johnson & Johnson appeal

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Supreme Court refuses to hear Saffran v Johnson & Johnson appeal

The US Supreme Court refused on Monday to hear an appeal from a doctor asking it to reinstate a $482 million patent infringement award against Johnson & Johnson subsidiary Cordis

The court declined to hear Saffran v Johnson & Johnson, in which radiologist Bruce Saffran claimed Cordis infringed a patent he obtained in 1997 in making its Cypher brand of drug-eluting stents, tiny mesh tubes used to prop open weak or narrow arteries.

A district court jury previously found that Cordis violate the patent. But a split Federal Circuit panel did not defer to the district court’s claim construction. The Federal Circuit changed the claim construction and overturned the district court’s finding that Cordis infringed the patent.

Saffran asked the appeals court to put his case on hold and reconsider it alongside Lighting Ballast v Philips, which concerns similar issues about the deference the Federal Circuit should give to a district court’s claim construction. But the Federal Circuit refused.

The Supreme Court’s refusal to accept the case means that Federal Circuit’s decision will stand.

The Supreme Court did not decide whether to accept the WildTangentvUltramercial case on Monday, instead electing to put the question of whether to hear it on hold. If the court chooses to accept that case, it will consider when a patent’s reference to a computer or the Internet is sufficient to make an otherwise unpatentable abstract idea eligible for patent protection.

The court may be waiting to decide whether to accept certiorari of WildTangentvUltramercial until it has resolved Alice v CLS Bank, which concerns similar issues and which the Supreme Court agreed to hear in December. Arguments in that case will take place on March 31 and a decision is expected by the end of June 2014.

more from across site and SHARED ros bottom lb

More from across our site

François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
The firm launched a San Diego office earlier this month, but California investment and expansion is far from complete
The industry’s response to AI requires an unfamiliar ingredient as firms battle to shape their futures
The firm is looking beyond replacing recently departed talent, betting instead on senior leaders to strengthen and expand its patent litigation platform
Olga Partington, director in Sterne Kessler’s biotechnology and chemical practice group, shares why a patent's vulnerability peaks when it is young, rather than when it is most valuable, under the PTAB's new framework
IP experts gathered in San Francisco last week to discuss the changing global SEP landscape and new licensing models for AI infrastructure
SKW Schwarz partner Daniel Kendziur explains how new green claims rules are changing his workload and bringing him into direct contact with marketing, PR and government affairs teams
The government is targeting earlier resolution of SEP disputes while ruling out a standalone IPEC rate determination track and restrictions on injunctions
Gift this article